<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Orf virus infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Orf virus infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Orf virus infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ossama Abbas, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4055105776"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Orf is a highly contagious, zoonotic, self-limited viral infection that threatens individuals who handle sheep and goats. The cause of orf is the orf virus. Other terms for orf include "ecthyma contagiosum," "infectious pustular dermatitis," and "contagious pustular dermatitis" [<a href="#rid1">1-4</a>].</p><p>In humans, orf usually presents as an evolving, erythematous nodule on the hand (<a class="graphic graphic_picture graphicRef117880" href="/d/graphic/117880.html" rel="external">picture 1A</a>). The infection typically resolves spontaneously within six to eight weeks.</p><p>The risk factors, clinical features, diagnosis, and management of orf virus infection will be reviewed here. Other zoonotic infections are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5531.html" rel="external">"Zoonoses: Animals other than dogs and cats"</a> and  <a class="medical medical_review" href="/d/html/5529.html" rel="external">"Zoonoses: Dogs"</a> and  <a class="medical medical_review" href="/d/html/5518.html" rel="external">"Zoonoses: Cats"</a>.)</p><p class="headingAnchor" id="H3321988869"><span class="h1">VIROLOGY</span><span class="headingEndMark"> — </span>The epitheliotropic orf virus is the prototype of the <em>Parapoxvirus</em> genus of Poxviridae family [<a href="#rid1">1-4</a>]. The virus has a linear double-stranded DNA genome and replicates within the host cell cytoplasm. The genome consists of a central core containing highly conserved genes that encode transcription and replication machinery; genes encoding factors associated with virulence, immune modulation, and pathogenesis are located outside the core region at both ends of the genome [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2562507736"><span class="h1">TRANSMISSION</span><span class="headingEndMark"> — </span>Orf virus is highly contagious. Loss of epithelial barrier integrity (ie, abrasion or other skin break) is the most important predisposing factor for infection [<a href="#rid1">1-4</a>].</p><p>Transmission to humans can occur through direct contact with an infected lesion on a living or deceased goat or sheep. Infected animals usually exhibit scabbed sores on or around the mouth, and the infection is commonly known as sore mouth or scabby mouth disease in sheep or goats [<a href="#rid5">5</a>]. Infections may also occur on the legs or udder teats, particularly in female animals that are nursing infected young.</p><p>In addition, infection can occur through contact with fomites previously contaminated by infected animals, such as farm buildings, wool, knives, buckets, equipment, and fences [<a href="#rid4">4,6</a>]. Orf virus is resilient and resistant to drying and freezing and can remain viable for months to years [<a href="#rid4">4,7</a>].</p><p>Autoinoculation and human-to-human transmission are rare [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H746377447"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Orf is most often an occupational hazard. Populations most at risk include shepherds, wool shearers, butchers, farmers, and veterinarians [<a href="#rid1">1,2,4,7</a>]. Less often, infection occurs in individuals with nonoccupational contact with sheep and goats, such as zoologic garden visitors and people who slaughter sheep or goats for traditional rituals [<a href="#rid4">4,6-11</a>].</p><p class="headingAnchor" id="H2271431132"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Orf virus causes a vesiculoulcerative infection of keratinized skin and mucosa that replicates in regenerating epidermal keratinocytes [<a href="#rid1">1-4</a>]. Multiple virulence factors contribute to immune evasion and the establishment of infection [<a href="#rid3">3,4</a>]. Host immunity, especially the cell-mediated immune response, plays a major role in limiting the severity of infection.</p><p>Virulence factors of the orf virus include proteins with anti-inflammatory functions (eg, viral-vascular endothelial growth factor, orf virus interleukin-10, ovine interferon resistance protein, a granulocyte-macrophage colony-stimulating factor inhibitory factor, and chemokine binding protein) and proteins that promote virus survival and host cell manipulation or exploitation (eg, orf virus-encoded deoxyuridine triphosphate [dUTP]ases, nuclear factor kappa-B modulatory factors, ankyrin repeat proteins, and gene 125-encoded proteins) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3343877548"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In immunocompetent patients, orf typically presents as a single asymptomatic lesion (approximately 1 cm in diameter) on the dorsa of hands or fingers that evolves in appearance over time (<a class="graphic graphic_picture graphicRef117880 graphicRef117882" href="/d/graphic/117880.html" rel="external">picture 1A-B</a>) [<a href="#rid1">1,2,4</a>]. Examples of less frequent sites include the head [<a href="#rid12">12</a>], axilla [<a href="#rid13">13</a>], and genitals [<a href="#rid14">14</a>]. Multiple lesions may also occur (<a class="graphic graphic_picture graphicRef117881" href="/d/graphic/117881.html" rel="external">picture 2</a>).</p><p>Orf lesions commonly appear three to seven days after inoculation and progress through six clinical stages over the course of six to eight weeks, ending in resolution. The duration of each stage is approximately one week [<a href="#rid1">1-4,6-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Maculopapular stage (solitary erythematous papule) (<a class="graphic graphic_picture graphicRef117882" href="/d/graphic/117882.html" rel="external">picture 1B</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Target stage (papule or nodule with gray-white, necrotic center and red outer halo) (<a class="graphic graphic_picture graphicRef118000" href="/d/graphic/118000.html" rel="external">picture 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute-nodular weepy stage (draining papule or nodule) (<a class="graphic graphic_picture graphicRef117880" href="/d/graphic/117880.html" rel="external">picture 1A</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Regenerative-nodular dry stage (firm, crusted papule or nodule) (<a class="graphic graphic_picture graphicRef118002" href="/d/graphic/118002.html" rel="external">picture 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Papilloma stage (papule or nodule with a papillomatous surface and dry crust) (<a class="graphic graphic_picture graphicRef117881" href="/d/graphic/117881.html" rel="external">picture 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Regression stage (lesion progressively shrinks in size and resolves, generally without residual scar) (<a class="graphic graphic_picture graphicRef118002" href="/d/graphic/118002.html" rel="external">picture 4</a>)</p><p></p><p>Rarely, fever, malaise, and lymphadenopathy accompany the skin lesion [<a href="#rid4">4,15</a>].</p><p>Immunocompromised patients, especially patients with inherited or acquired T cell dysfunction, may develop atypical, painful, persistent giant orf lesions up to several centimeters in diameter [<a href="#rid16">16-23</a>]. Tumor-like and pyogenic granuloma-like morphologies may occur in these patients. Rarely, giant orf occurs in immunocompetent individuals [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1441414677"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Potential complications include secondary bacterial infections and lymphangitis. In addition, orf is occasionally associated with the induction of secondary immunologic reactions, such as erythema multiforme [<a href="#rid25">25,26</a>], widespread papulovesicular eruptions [<a href="#rid15">15,27</a>], id reactions [<a href="#rid28">28,29</a>], and autoimmune blistering diseases [<a href="#rid26">26,30-34</a>].</p><p>Anti-laminin 332 antibodies may play a role in orf-induced autoimmune blistering disease. In a case series of five patients with orf-induced autoimmune blistering disease, anti-laminin 332 antibodies were identified in all patients [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H2681619403"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Microscopic findings may vary depending on the clinical stage of the lesion. Characteristic features of orf include (<a class="graphic graphic_picture graphicRef117883" href="/d/graphic/117883.html" rel="external">picture 5</a>) [<a href="#rid3">3,4,35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Overlying crust</p><p class="bulletIndent1"><span class="glyph">●</span>Parakeratosis</p><p class="bulletIndent1"><span class="glyph">●</span>Irregular epidermal hyperplasia</p><p class="bulletIndent1"><span class="glyph">●</span>Keratinocyte ballooning and degeneration</p><p class="bulletIndent1"><span class="glyph">●</span>Intraepidermal vesiculation</p><p class="bulletIndent1"><span class="glyph">●</span>Intracytoplasmic and intranuclear inclusions within vacuolated keratinocytes (<a class="graphic graphic_picture graphicRef117884" href="/d/graphic/117884.html" rel="external">picture 6</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased dermal vascularity</p><p class="bulletIndent1"><span class="glyph">●</span>Papillary dermal edema</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed inflammatory cell infiltrate</p><p></p><p class="headingAnchor" id="H1228346716"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The patient history and physical examination are usually sufficient for diagnosis. The collection of findings that strongly support the diagnosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute development of a papule or nodule exhibiting features consistent with one of the stages of orf</p><p class="bulletIndent1"><span class="glyph">●</span>Recent exposure to an infected sheep or goat or objects contaminated by an infected sheep or goat</p><p></p><p>When the diagnosis is in doubt, a biopsy or molecular testing can aid in confirming the diagnosis [<a href="#rid2">2-4</a>]. A shave or punch biopsy can either reveal features supportive of viral infection (eg, intracytoplasmic and intranuclear inclusions within vacuolated keratinocytes) and other supportive features of orf or identify findings that are more consistent with other diseases. (See <a class="local">'Histopathology'</a> above.)</p><p>Although not available in all settings, both standard and real-time polymerase chain reaction (PCR) testing are rapid and sensitive methods for diagnosing orf, with real-time PCR being highly sensitive [<a href="#rid4">4,36,37</a>]. A skin biopsy provides an adequate specimen. Other less widely used methods for confirming the diagnosis include cell culture and electron microscopy [<a href="#rid2">2,4</a>]. In addition, a sensitive and specific recombinase-aided amplification (RAA) assay for orf virus detection has been developed. In a study of 45 nasal scab skin samples examined by RAA and real-time PCR, the clinical performance of RAA was comparable with that of real-time PCR assay, while being faster, less expensive, and technically simpler [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3409089925"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical differential diagnosis is extensive. In particular, orf should be distinguished from milker's nodule and cutaneous anthrax, infections that may also result in vesiculoulcerative lesions following contact with animals:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Milker's nodule</strong> – Milker's nodule (also known as paravaccinia) is a parapoxvirus infection humans can acquire from dairy cows. Milker's nodule usually appears as one or more red-blue, smooth, verrucous, or vesicular nodules on the hand or arms and may be clinically indistinguishable from orf lesions (<a class="graphic graphic_picture graphicRef118029" href="/d/graphic/118029.html" rel="external">picture 7</a>). Like orf, milker's nodule typically spontaneously resolves over the course of several weeks. The history of acquisition from contact with cows rather than sheep or goats is helpful for distinguishing these diseases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous anthrax</strong> – Cutaneous anthrax is an infection that may result from contact with infected animals, animal meat, hides, or wool. <em>Bacillus anthracis</em>, a gram-positive bacillus, is the causative organism. Affected patients typically present with a nonpainful papule that subsequently vesiculates and evolves into an ulcer with black eschar (<a class="graphic graphic_picture graphicRef73444" href="/d/graphic/73444.html" rel="external">picture 8</a>). Gram stain, culture, and polymerase chain reaction (PCR) tests can confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/5533.html" rel="external">"Clinical manifestations and diagnosis of anthrax", section on 'Cutaneous anthrax'</a>.)</p><p></p><p>Other infections that may present with papules or nodules that may be mistaken for orf virus infection include giant molluscum, atypical mycobacterial infections, paronychia (<a class="graphic graphic_picture graphicRef117882" href="/d/graphic/117882.html" rel="external">picture 1B</a>), cutaneous leishmaniasis, herpetic whitlow, tularemia, and sporotrichosis. Neoplastic entities, such as keratoacanthoma and pyogenic granuloma, are also in the differential diagnosis [<a href="#rid4">4,18,39,40</a>]. The patient history and clinical findings are often sufficient for differentiating orf from these disorders.</p><p class="headingAnchor" id="H2326776077"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>In immunocompetent patients, treatment is not necessary since the infection spontaneously resolves within several weeks. Topical antiseptics can be used to minimize risk for secondary bacterial infections [<a href="#rid1">1,4</a>].</p><p>Immunocompromised patients may develop giant persistent lesions and may require intervention for resolution. Case reports describe successful treatment with cryotherapy, electrocautery, curettage, <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a>, intralesional interferon injections, or topical <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> [<a href="#rid4">4,18,20-23,41</a>]. Wide local excision has been performed for refractory infections that cannot be managed with less invasive therapies, but recurrence after excision is common [<a href="#rid4">4</a>]. No randomized trials evaluating the efficacy of therapies have been performed.</p><p class="headingAnchor" id="H2673367218"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Reinfection with orf virus can occur. However, reinfection is commonly characterized by decreased lesion size and faster resolution [<a href="#rid1">1,2,4</a>].</p><p>Use of nonpermeable gloves when handling infected animals may reduce risk for human infection. Orf virus vaccines have been used in animals but appear only partially effective and are not available for use in humans [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H1581630454"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Virology and transmission</strong> – Orf is a cutaneous viral infection caused by infection with the orf virus, a parapoxvirus that infects sheep and goats. Humans may acquire the infection from contact with infected animals or contaminated fomites. Populations most at risk for orf include shepherds, wool shearers, butchers, farmers, and veterinarians. (See <a class="local">'Virology'</a> above and <a class="local">'Transmission'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Orf usually manifests as a solitary papule or nodule that evolves through six clinical stages over the course of six to eight weeks (<a class="graphic graphic_picture graphicRef117880 graphicRef117882" href="/d/graphic/117880.html" rel="external">picture 1A-B</a>). Multiple and giant lesions may also occur, particularly in immunocompromised patients. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">The six clinical stages of orf include the maculopapular stage, target stage, acute-nodular weepy stage, regenerative-nodular dry stage, papilloma stage, and regression stage. Fever, malaise, or lymphadenopathy occasionally accompany the skin lesion. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Orf usually can be diagnosed based upon the patient history and physical examination. A biopsy or molecular testing can aid in confirming the diagnosis in difficult cases. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Orf generally spontaneously resolves within several weeks. Persistent infection may occur in immunocompromised patients. Data on treatment of persistent infection are limited. Treatments that have seemed beneficial in case reports include cryotherapy, electrocautery, curettage, <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a>, intralesional interferon injections, or <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>. Recurrence is common after wide local excision. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Haig DM, Mercer AA. Ovine diseases. Orf. Vet Res 1998; 29:311.</a></li><li><a class="nounderline abstract_t">Hosamani M, Scagliarini A, Bhanuprakash V, et al. Orf: an update on current research and future perspectives. Expert Rev Anti Infect Ther 2009; 7:879.</a></li><li><a class="nounderline abstract_t">Fleming SB, Wise LM, Mercer AA. Molecular genetic analysis of orf virus: a poxvirus that has adapted to skin. Viruses 2015; 7:1505.</a></li><li><a class="nounderline abstract_t">Bergqvist C, Kurban M, Abbas O. Orf virus infection. Rev Med Virol 2017; 27.</a></li><li class="breakAll">US Centers for Disease Control and Prevention. Orf Virus (Sore Mouth Infection): Infection in Animals. www.cdc.gov/poxvirus/orf-virus/animals.html (Accessed on June 05, 2018).</li><li><a class="nounderline abstract_t">Duchateau NC, Aerts O, Lambert J. Autoinoculation with Orf virus (ecthyma contagiosum). Int J Dermatol 2014; 53:e60.</a></li><li><a class="nounderline abstract_t">Bayindir Y, Bayraktar M, Karadag N, et al. Investigation and analysis of a human orf outbreak among people living on the same farm. New Microbiol 2011; 34:37.</a></li><li><a class="nounderline abstract_t">Robinson AJ, Petersen GV. Orf virus infection of workers in the meat industry. N Z Med J 1983; 96:81.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Human Orf virus infection from household exposures - United States, 2009-2011. MMWR Morb Mortal Wkly Rep 2012; 61:245.</a></li><li><a class="nounderline abstract_t">Uzel M, Sasmaz S, Bakaris S, et al. A viral infection of the hand commonly seen after the feast of sacrifice: human orf (orf of the hand). Epidemiol Infect 2005; 133:653.</a></li><li><a class="nounderline abstract_t">Veraldi S, Esposito L, Pontini P, et al. Feast of Sacrifice and Orf, Milan, Italy, 2015-2018. Emerg Infect Dis 2019; 25:1585.</a></li><li><a class="nounderline abstract_t">Turk BG, Senturk B, Dereli T, Yaman B. A rare human-to-human transmission of orf. Int J Dermatol 2014; 53:e63.</a></li><li><a class="nounderline abstract_t">Weide B, Metzler G, Eigentler TK, et al. Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. Clin Exp Dermatol 2009; 34:240.</a></li><li><a class="nounderline abstract_t">Kandemir H, Ciftcioglu MA, Yilmaz E. Genital ORF. Eur J Dermatol 2008; 18:460.</a></li><li><a class="nounderline abstract_t">Wilkinson JD. Orf: a family with unusual complications. Br J Dermatol 1977; 97:447.</a></li><li><a class="nounderline abstract_t">Tan ST, Blake GB, Chambers S. Recurrent orf in an immunocompromised host. Br J Plast Surg 1991; 44:465.</a></li><li><a class="nounderline abstract_t">Kilic SS, Puel A, Casanova JL. Orf Infection in a Patient with Stat1 Gain-of-Function. J Clin Immunol 2015; 35:80.</a></li><li><a class="nounderline abstract_t">Ran M, Lee M, Gong J, et al. Oral Acyclovir and Intralesional Interferon Injections for Treatment of Giant Pyogenic Granuloma-Like Lesions in an Immunocompromised Patient With Human Orf. JAMA Dermatol 2015; 151:1032.</a></li><li><a class="nounderline abstract_t">Ballanger F, Barbarot S, Mollat C, et al. Two giant orf lesions in a heart/lung transplant patient. Eur J Dermatol 2006; 16:284.</a></li><li><a class="nounderline abstract_t">Zaharia D, Kanitakis J, Pouteil-Noble C, Euvrard S. Rapidly growing orf in a renal transplant recipient: favourable outcome with reduction of immunosuppression and imiquimod. Transpl Int 2010; 23:e62.</a></li><li><a class="nounderline abstract_t">Degraeve C, De Coninck A, Senneseael J, Roseeuw D. Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cryotherapy. Dermatology 1999; 198:162.</a></li><li><a class="nounderline abstract_t">Geerinck K, Lukito G, Snoeck R, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol 2001; 64:543.</a></li><li><a class="nounderline abstract_t">Harms J, Swick BL, Wanat KA. Pyogenic granuloma-like orf in a transplant patient treated successfully with excision and imiquimod. JAAD Case Rep 2019; 5:566.</a></li><li><a class="nounderline abstract_t">Key SJ, Catania J, Mustafa SF, et al. Unusual presentation of human giant orf (ecthyma contagiosum). J Craniofac Surg 2007; 18:1076.</a></li><li><a class="nounderline abstract_t">Joseph RH, Haddad FA, Matthews AL, et al. Erythema multiforme after orf virus infection: a report of two cases and literature review. Epidemiol Infect 2015; 143:385.</a></li><li><a class="nounderline abstract_t">Alian S, Ahangarkani F, Arabsheybani S. A Case of Orf Disease Complicated with Erythema Multiforme and Bullous Pemphigoid-Like Eruptions. Case Rep Infect Dis 2015; 2015:105484.</a></li><li><a class="nounderline abstract_t">Bassioukas K, Orfanidou A, Stergiopoulou CH, Hatzis J. Orf. Clinical and epidemiological study. Australas J Dermatol 1993; 34:119.</a></li><li><a class="nounderline abstract_t">Haddock ES, Cheng CE, Bradley JS, et al. Extensive orf infection in a toddler with associated id reaction. Pediatr Dermatol 2017; 34:e337.</a></li><li><a class="nounderline abstract_t">Curtiss P, Svigos K, Chacko M, et al. Bullous id eruption in the setting of orf. Br J Dermatol 2018; 178:986.</a></li><li><a class="nounderline abstract_t">Macfarlane AW. Human orf complicated by bullous pemphigoid. Br J Dermatol 1997; 137:656.</a></li><li><a class="nounderline abstract_t">Zuelgaray E, Salle de Chou C, Gottlieb J, et al. Human orf complicated by epidermolysis bullosa acquisita. Br J Dermatol 2018; 178:547.</a></li><li><a class="nounderline abstract_t">White KP, Zedek DC, White WL, et al. Orf-induced immunobullous disease: A distinct autoimmune blistering disorder. J Am Acad Dermatol 2008; 58:49.</a></li><li><a class="nounderline abstract_t">Carmichael AJ, Harman KE. Orf - a potential trigger for self-limiting epidermolysis bullosa acquisita-like blistering. Br J Dermatol 2018; 178:333.</a></li><li><a class="nounderline abstract_t">Yilmaz K, Goletz S, Pas HH, et al. Clinical and Serological Characterization of Orf-Induced Immunobullous Disease. JAMA Dermatol 2022; 158:670.</a></li><li><a class="nounderline abstract_t">Saadeh D, Kurban M, Kibbi AG, Abbas O. Involvement of plasmacytoid dendritic cells in the immunological response against Orf infection. JAMA Dermatol 2014; 150:1112.</a></li><li><a class="nounderline abstract_t">Bora DP, Venkatesan G, Bhanuprakash V, et al. TaqMan real-time PCR assay based on DNA polymerase gene for rapid detection of Orf infection. J Virol Methods 2011; 178:249.</a></li><li><a class="nounderline abstract_t">Töndury B, Kühne A, Kutzner H, et al. Molecular diagnostics of parapox virus infections. J Dtsch Dermatol Ges 2010; 8:681.</a></li><li><a class="nounderline abstract_t">Wang Y, Cui Y, Yu Z, et al. Development of a recombinase-aided amplification assay for detection of orf virus. J Virol Methods 2020; 280:113861.</a></li><li><a class="nounderline abstract_t">Handler NS, Handler MZ, Rubins A, et al. Milker's nodule: an occupational infection and threat to the immunocompromised. J Eur Acad Dermatol Venereol 2018; 32:537.</a></li><li><a class="nounderline abstract_t">Durdu M, Ruocco V. Clinical and cytologic features of antibiotic-resistant acute paronychia. J Am Acad Dermatol 2014; 70:120.</a></li><li><a class="nounderline abstract_t">Ertekin SS, Gurel MS, Erdemir AVT, Leblebici C. Systemic interferon alfa injections for the treatment of a giant orf. Cutis 2017; 99:E19.</a></li><li><a class="nounderline abstract_t">Zhao K, He W, Gao W, et al. Orf virus DNA vaccines expressing ORFV 011 and ORFV 059 chimeric protein enhances immunogenicity. Virol J 2011; 8:562.</a></li><li><a class="nounderline abstract_t">Bala JA, Balakrishnan KN, Abdullah AA, et al. The re-emerging of orf virus infection: A call for surveillance, vaccination and effective control measures. Microb Pathog 2018; 120:55.</a></li></ol></div><div id="topicVersionRevision">Topic 110105 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9689744" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ovine diseases. Orf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19735227" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Orf: an update on current research and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25807056" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular genetic analysis of orf virus: a poxvirus that has adapted to skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480985" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Orf virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480985" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Orf virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23286456" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Autoinoculation with Orf virus (ecthyma contagiosum).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21344145" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Investigation and analysis of a human orf outbreak among people living on the same farm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6571964" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Orf virus infection of workers in the meat industry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495228" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human Orf virus infection from household exposures - United States, 2009-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16050510" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A viral infection of the hand commonly seen after the feast of sacrifice: human orf (orf of the hand).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31310206" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Feast of Sacrifice and Orf, Milan, Italy, 2015-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557377" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A rare human-to-human transmission of orf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120403" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Inflammatory nodules around the axilla: an uncommon localization of orf virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573724" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genital ORF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/588455" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Orf: a family with unusual complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1933121" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrent orf in an immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25367169" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Orf Infection in a Patient with Stat1 Gain-of-Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946461" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Oral Acyclovir and Intralesional Interferon Injections for Treatment of Giant Pyogenic Granuloma-Like Lesions in an Immunocompromised Patient With Human Orf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709495" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Two giant orf lesions in a heart/lung transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20681978" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rapidly growing orf in a renal transplant recipient: favourable outcome with reduction of immunosuppression and imiquimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325465" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cryotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11468742" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A case of human orf in an immunocompromised patient treated successfully with cidofovir cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31245523" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pyogenic granuloma-like orf in a transplant patient treated successfully with excision and imiquimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17912086" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Unusual presentation of human giant orf (ecthyma contagiosum).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24810660" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Erythema multiforme after orf virus infection: a report of two cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26294986" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A Case of Orf Disease Complicated with Erythema Multiforme and Bullous Pemphigoid-Like Eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080415" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Orf. Clinical and epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940500" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Extensive orf infection in a toddler with associated id reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29278413" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bullous id eruption in the setting of orf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390357" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Human orf complicated by bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28338219" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Human orf complicated by epidermolysis bullosa acquisita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919774" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Orf-induced immunobullous disease: A distinct autoimmune blistering disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29441548" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Orf - a potential trigger for self-limiting epidermolysis bullosa acquisita-like blistering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35353128" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical and Serological Characterization of Orf-Induced Immunobullous Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162907" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Involvement of plasmacytoid dendritic cells in the immunological response against Orf infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21946289" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : TaqMan real-time PCR assay based on DNA polymerase gene for rapid detection of Orf infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20497283" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Molecular diagnostics of parapox virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32343981" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Development of a recombinase-aided amplification assay for detection of orf virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29125649" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Milker's nodule: an occupational infection and threat to the immunocompromised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355264" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical and cytologic features of antibiotic-resistant acute paronychia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632812" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Systemic interferon alfa injections for the treatment of a giant orf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22204310" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Orf virus DNA vaccines expressing ORFV 011 and ORFV 059 chimeric protein enhances immunogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29709684" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The re-emerging of orf virus infection: A call for surveillance, vaccination and effective control measures.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
